|Bid||0.00 x 1200|
|Ask||0.00 x 800|
|Day's Range||4.0500 - 4.6400|
|52 Week Range||3.1300 - 8.4190|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 13, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
Pfenex Inc. (NYSE American: PFNX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the 505(b)(2) New Drug Application (NDA) for the Company’s lead product candidate, PF708, a Forteo® therapeutic equivalent in the treatment of osteoporosis, which achieved $1.6 billion in global product sales in 2018. The acceptance of the NDA indicates the application is sufficiently complete to permit a substantive review by the FDA.
Pfenex Inc. (NYSE American: PFNX) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of PF708 for the treatment of osteoporosis. The application is submitted as a 505(b)(2) NDA and references Eli Lilly and Company’s Forteo® (teriparatide) as the Reference Listed Drug.
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Pfenex, Inc. (NYSE American: PFNX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time. ...
- PF708-301 findings show comparable overall profiles of PF708 and Forteo® - No imbalances in severity or incidence of adverse events - Company is on track for submission of NDA in third quarter 2018 - ...
SAN DIEGO , May 10, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pf ēnex Expression Technology ® to ...